MAFLD: The Hidden Condition Behind Fatty Liver & What You Can Do

Synopsis

MAFLD is a common but often silent condition where excess fat builds up in the liver due to insulin resistance, abnormal blood fats and raised blood glucose. Once rare in younger people, it is now increasingly diagnosed in adults in their 20s and 30s. Beyond the liver, it significantly raises the risk of heart disease, stroke and certain cancers. The good news is that early-stage MAFLD is largely reversible through lifestyle changes and, where needed, medication. This article explains what causes it, how it is diagnosed, and the practical steps you can take to improve it.

If you've recently been told you have MAFLD, you may never have heard the term before. You're not alone. MAFLD stands for Metabolic dysfunction-Associated Fatty Liver Disease, a condition where excess fat builds up in the liver, driven not by alcohol, but by problems with how the body processes energy: insulin resistance, abnormal blood fats, raised blood glucose, and inflammation around the internal organs. It's remarkably common, affecting roughly one in four adults worldwide, and most people who have it feel completely well. That's precisely why understanding it matters: it's a condition you can catch early, and in most cases, substantially improve.

It's getting younger

Something has changed in my clinic over recent years. I am now seeing more and more people in their 20s and 30s being diagnosed with this condition, an age group in which fatty liver was once rare. The reasons aren't mysterious: diets increasingly built around ultra-processed, high-sugar convenience foods, sugary drinks, long hours sitting at desks and in cars, and not nearly enough regular exercise. The data back this up, rates of MAFLD in adolescents and young adults have been climbing steadily for three decades, driven by exactly these lifestyle factors. The concerning part is that developing MAFLD young means a longer lifetime of exposure to its risks, which makes early diagnosis and action even more valuable.

From "fatty liver" to a meaningful diagnosis

For years, this condition was called NAFLD (non-alcoholic fatty liver disease). The name change to MAFLD reflects a better understanding of what's actually going on. The old name defined the disease by what it wasn't (not caused by alcohol). The new name defines it by what it is: a liver condition rooted in metabolic dysfunction. MAFLD isn't really a liver problem in isolation, it's the liver's visible sign that the body's metabolism is under strain.

What's actually happening inside the body

Insulin resistance: the engine of the problem

Insulin is the hormone that moves glucose (sugar) from your bloodstream into your cells. In insulin resistance, your cells stop responding properly to insulin's signal. Your pancreas compensates by producing more and more insulin, and while blood glucose may stay near normal for a time, the excess insulin itself causes harm. High insulin levels instruct the liver to manufacture and store fat. Over time, fat accumulates inside liver cells. This is the starting point of MAFLD for most people.

Raised blood glucose and pre-diabetes

As insulin resistance progresses, the pancreas struggles to keep up, and blood glucose creeps upward, first into the range doctors call pre-diabetes: higher than ideal, but not yet at the level defining type 2 diabetes. Pre-diabetes matters twice over. It's a warning sign that diabetes may follow within years, and it forms a vicious cycle with fatty liver. High glucose promotes more liver fat, and a fatty liver worsens insulin resistance. It's usually detected with simple blood tests, such as a fasting glucose or a test reflecting your average blood glucose over the previous few months.

Raised cholesterol and abnormal blood fats

The cholesterol picture in MAFLD differs from what most people expect. Rather than simply "high cholesterol," the typical pattern is raised triglycerides (a type of blood fat), low HDL ("good") cholesterol, and a shift towards more harmful cholesterol particles, all picked up on standard cholesterol blood tests. These abnormal fats travel alongside the fatty liver, and together they significantly raise the risk of heart disease and stroke.

Visceral fat and inflammation

Not all body fat behaves the same. Fat under the skin of your arms and legs is relatively harmless. Visceral fat, packed deep inside the abdomen around your organs, is biologically active in a harmful way, releasing inflammatory signals and fatty acids directly into the blood vessel that drains straight into the liver. Visceral fat essentially infiltrates the liver with fat and inflammation. This is why MAFLD can occur even in people of normal weight; some carry hidden visceral fat ("thin outside, fat inside"). Waist circumference is a crude but useful clue.

How is MAFLD diagnosed?

MAFLD is often first suspected when routine blood tests show mildly abnormal liver enzymes, or when a health check reveals raised glucose or triglycerides alongside other metabolic features. Blood tests alone can't stage the condition, so doctors commonly combine them into scoring systems to estimate the likelihood of liver scarring.

Two scans are worth knowing about:

FibroScan: a painless, ultrasound-based test done in clinic that measures both the amount of fat in the liver and how stiff the liver is. Stiffness is a marker of scarring (fibrosis): the stiffer the liver, the more advanced the damage. It takes only a few minutes.
DEXA scan: best known for measuring bone density, a DEXA scan also maps body composition in detail, including precisely how much visceral fat you carry. It can be a useful way to quantify the hidden internal fat driving the condition, even in people who look slim.

In some cases, further imaging or (rarely) a liver biopsy is needed. In a proportion of people, the combination of fat and inflammation tips the liver into a more serious stage where cells are damaged and scarring begins; persistent scarring can eventually lead to cirrhosis.

The wider risks: heart disease, stroke and cancer

This is the part many people don't realise. The leading cause of serious illness in people with MAFLD isn't liver failure; it's cardiovascular disease. Large studies show that fatty liver disease is associated with a substantially higher risk of heart attack, stroke and cardiovascular death, even after accounting for traditional risk factors.

There is also a cancer connection. People with MAFLD have around double the risk of liver cancer, with the risk rising sharply as scarring advances. More surprisingly, research shows a modestly increased risk of several cancers outside the liver, including bowel, pancreatic, oesophageal, breast and lung cancers, and in this population, cancers outside the liver are actually far more common than liver cancer itself. This is thought to reflect the chronic, body-wide inflammation and metabolic disturbance that MAFLD represents.

None of this is said to frighten you; these are increases in risk, not certainties. But it's exactly why MAFLD deserves to be taken seriously rather than dismissed as "just a bit of fat on the liver."

The good news: MAFLD is often reversible

In its early and middle stages, MAFLD frequently improves, sometimes dramatically, with lifestyle change. The liver is a remarkably regenerative organ.

Weight loss is the single most powerful treatment.

Losing around 5% of body weight reduces liver fat; 7–10% or more can reduce liver inflammation and even reverse early scarring. You don't need to reach a "perfect" weight, the trajectory matters more than the destination.

Diet quality counts, not just calories.

A Mediterranean-style pattern, vegetables, fruit, wholegrains, legumes, fish, olive oil, nuts, has the best evidence. The two things to actively reduce are sugary drinks (the fructose in sweetened beverages is particularly effective at driving liver fat) and highly processed foods. Keep alcohol low; some people with significant liver disease are advised to avoid it entirely.

Exercise works even without weight loss.

Both aerobic exercise (brisk walking, cycling, swimming) and resistance training reduce liver fat and improve insulin sensitivity directly. Aim for at least 150 minutes of moderate activity weekly, plus some strength work and if you're in your 20s or 30s reading this, building these habits now is the single best investment you can make.

Medical treatments support but don't replace lifestyle change.

Depending on your situation, your doctor may discuss:

Cholesterol-lowering medication (usually a statin). Statins are safe in fatty liver disease and often recommended because of the elevated cardiovascular risk and may even reduce liver cancer risk.
Glucose-lowering medication for pre-diabetes or type 2 diabetes. Some of these drugs have the welcome side benefits of weight loss and reducing liver fat, and newer agents are now being approved in some regions specifically for the inflammatory form of fatty liver disease.
Blood pressure management, as part of reducing overall cardiovascular risk.
For selected patients with more advanced disease, weight-loss medications or bariatric surgery, which can produce striking improvements in the liver.

Monitoring and the bigger picture

If you have MAFLD, expect periodic blood tests to track liver enzymes, glucose control and cholesterol, along with occasional scans to reassess liver fat and scarring. But think of the diagnosis less as a liver verdict and more as an early warning light for your whole metabolic health: a chance to act on insulin resistance, cholesterol, blood pressure and visceral fat years before they might otherwise have been detected, and before they raise your risk of heart disease, stroke and cancer.

MAFLD is common, increasingly affecting young adults, usually silent and largely modifiable. If you've been given this diagnosis, see it not as bad news, but as useful news: a clear signal, delivered early, with a well-understood path to putting things right.

Dr Ray SH Ng

Family Medicine, General Practice, Sports Medicine

MBBS (London)
MRCP (UK)
MRCGP (UK)
PgDipPD (Cardiff)

View Profile

Health Articles by Dr Ray SH Ng

Interviews

Reference

European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity (2024) 'EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary', Diabetologia, 67(11), pp. 2375–2392. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11519095/ [Accessed 8 September 2026].